TransThera Sciences (HKG:2617) widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.
The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.
The firm did not record any revenue in both periods.
Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments